Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

Ayana Tomono, Kaori Ito, Takahiro Hayashi, Maiko Ando, Yosuke Ando, Masahiro Tsuge, Akinao Okamoto, Yoko Inaguma, Masataka Okamoto, Nobuhiko Emi, Shigeki Yamada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Several studies have evaluated the utility of extrapolating the Calvert formula in calculating carboplatin (CBDCA) dosages in solid tumours; however, data regarding haematological cancers are less. Therefore, we conducted a preliminary study of the utility of extrapolating the Calvert formula in calculating CBDCA dosages for DeVIC ± R therapy. Methods: A retrospective study on 57 non-Hodgkin lymphoma patients who had received DeVIC ± R therapy was conducted. The area under the curve (AUC) of CBDCA was back-calculated from actual dosages using the Calvert formula. Patients were divided into two groups according to an AUC ≥ 4 or an AUC < 4, respectively. The Revised Response Criteria of the International Working Group and CTCAE version 4.0 were used for assessing the treatment efficacy and adverse events, respectively. Results: The use of AUC instead of body surface area had greater utility in calculating CBDCA dosage, with a response rate of greater than 50 % in patients receiving DeVIC ± R therapy with an AUC ≥ 4 for CBDCA. The response rate of the AUC ≥ 4 group was significantly higher than that of the AUC < 4 group. Decreased platelet and neutrophil counts of grade ≥3 occurred at higher rates in the AUC ≥ 4 group. Conclusion: The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4.

Original languageEnglish
Pages (from-to)305-312
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume78
Issue number2
DOIs
Publication statusPublished - 01-08-2016

Fingerprint

Salvaging
Salvage Therapy
Ifosfamide
Carboplatin
Etoposide
Refractory materials
Non-Hodgkin's Lymphoma
Dexamethasone
Area Under Curve
Therapeutics
Rituximab
Body Surface Area
Platelets
Platelet Count
Extrapolation
Tumors
Neoplasms
Neutrophils
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

@article{d4799616981b4fd5aee92c9988c807e0,
title = "Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma",
abstract = "Purpose: Several studies have evaluated the utility of extrapolating the Calvert formula in calculating carboplatin (CBDCA) dosages in solid tumours; however, data regarding haematological cancers are less. Therefore, we conducted a preliminary study of the utility of extrapolating the Calvert formula in calculating CBDCA dosages for DeVIC ± R therapy. Methods: A retrospective study on 57 non-Hodgkin lymphoma patients who had received DeVIC ± R therapy was conducted. The area under the curve (AUC) of CBDCA was back-calculated from actual dosages using the Calvert formula. Patients were divided into two groups according to an AUC ≥ 4 or an AUC < 4, respectively. The Revised Response Criteria of the International Working Group and CTCAE version 4.0 were used for assessing the treatment efficacy and adverse events, respectively. Results: The use of AUC instead of body surface area had greater utility in calculating CBDCA dosage, with a response rate of greater than 50 {\%} in patients receiving DeVIC ± R therapy with an AUC ≥ 4 for CBDCA. The response rate of the AUC ≥ 4 group was significantly higher than that of the AUC < 4 group. Decreased platelet and neutrophil counts of grade ≥3 occurred at higher rates in the AUC ≥ 4 group. Conclusion: The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4.",
author = "Ayana Tomono and Kaori Ito and Takahiro Hayashi and Maiko Ando and Yosuke Ando and Masahiro Tsuge and Akinao Okamoto and Yoko Inaguma and Masataka Okamoto and Nobuhiko Emi and Shigeki Yamada",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00280-016-3076-9",
language = "English",
volume = "78",
pages = "305--312",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma. / Tomono, Ayana; Ito, Kaori; Hayashi, Takahiro; Ando, Maiko; Ando, Yosuke; Tsuge, Masahiro; Okamoto, Akinao; Inaguma, Yoko; Okamoto, Masataka; Emi, Nobuhiko; Yamada, Shigeki.

In: Cancer Chemotherapy and Pharmacology, Vol. 78, No. 2, 01.08.2016, p. 305-312.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

AU - Tomono, Ayana

AU - Ito, Kaori

AU - Hayashi, Takahiro

AU - Ando, Maiko

AU - Ando, Yosuke

AU - Tsuge, Masahiro

AU - Okamoto, Akinao

AU - Inaguma, Yoko

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

AU - Yamada, Shigeki

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose: Several studies have evaluated the utility of extrapolating the Calvert formula in calculating carboplatin (CBDCA) dosages in solid tumours; however, data regarding haematological cancers are less. Therefore, we conducted a preliminary study of the utility of extrapolating the Calvert formula in calculating CBDCA dosages for DeVIC ± R therapy. Methods: A retrospective study on 57 non-Hodgkin lymphoma patients who had received DeVIC ± R therapy was conducted. The area under the curve (AUC) of CBDCA was back-calculated from actual dosages using the Calvert formula. Patients were divided into two groups according to an AUC ≥ 4 or an AUC < 4, respectively. The Revised Response Criteria of the International Working Group and CTCAE version 4.0 were used for assessing the treatment efficacy and adverse events, respectively. Results: The use of AUC instead of body surface area had greater utility in calculating CBDCA dosage, with a response rate of greater than 50 % in patients receiving DeVIC ± R therapy with an AUC ≥ 4 for CBDCA. The response rate of the AUC ≥ 4 group was significantly higher than that of the AUC < 4 group. Decreased platelet and neutrophil counts of grade ≥3 occurred at higher rates in the AUC ≥ 4 group. Conclusion: The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4.

AB - Purpose: Several studies have evaluated the utility of extrapolating the Calvert formula in calculating carboplatin (CBDCA) dosages in solid tumours; however, data regarding haematological cancers are less. Therefore, we conducted a preliminary study of the utility of extrapolating the Calvert formula in calculating CBDCA dosages for DeVIC ± R therapy. Methods: A retrospective study on 57 non-Hodgkin lymphoma patients who had received DeVIC ± R therapy was conducted. The area under the curve (AUC) of CBDCA was back-calculated from actual dosages using the Calvert formula. Patients were divided into two groups according to an AUC ≥ 4 or an AUC < 4, respectively. The Revised Response Criteria of the International Working Group and CTCAE version 4.0 were used for assessing the treatment efficacy and adverse events, respectively. Results: The use of AUC instead of body surface area had greater utility in calculating CBDCA dosage, with a response rate of greater than 50 % in patients receiving DeVIC ± R therapy with an AUC ≥ 4 for CBDCA. The response rate of the AUC ≥ 4 group was significantly higher than that of the AUC < 4 group. Decreased platelet and neutrophil counts of grade ≥3 occurred at higher rates in the AUC ≥ 4 group. Conclusion: The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4.

UR - http://www.scopus.com/inward/record.url?scp=84975257294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975257294&partnerID=8YFLogxK

U2 - 10.1007/s00280-016-3076-9

DO - 10.1007/s00280-016-3076-9

M3 - Article

VL - 78

SP - 305

EP - 312

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -